July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Pre-Commercialization of Agmatine Antiglaucoma Eye Drops
Author Affiliations & Notes
  • Samin Hong
    Ophthalmology, Yonsei University College of Medicine, Seoul, Korea (the Republic of)
    Optic Nerve Regeneration & Stem Cell Research Institute, Hong Samin Yonsei Eye Clinic, Seoul, Korea (the Republic of)
  • Yeon Soo Chung
    Eyegene, Inc., Seoul, Korea (the Republic of)
  • Hyun Jong Kim
    Eyegene, Inc., Seoul, Korea (the Republic of)
  • Yang Je Cho
    Eyegene, Inc., Seoul, Korea (the Republic of)
  • Chan Yun Kim
    Ophthalmology, Yonsei University College of Medicine, Seoul, Korea (the Republic of)
    Yonsei Institute of Vision Research, Seoul, Korea (the Republic of)
  • Gong Je Seong
    Ophthalmology, Yonsei University College of Medicine, Seoul, Korea (the Republic of)
    Yonsei Institute of Vision Research, Seoul, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Samin Hong, Yonsei University College of Medicine (P); Yeon Soo Chung, Eyegene, Inc. (E); Hyun Jong Kim, Eyegene, Inc. (E); Yang Je Cho, Eyegene, Inc. (E); Chan Yun Kim, Yonsei University College of Medicine (P); Gong Je Seong, Yonsei University College of Medicine (P)
  • Footnotes
    Support  Small and Medium Business Administration of South Korea
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1244. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Samin Hong, Yeon Soo Chung, Hyun Jong Kim, Yang Je Cho, Chan Yun Kim, Gong Je Seong; Pre-Commercialization of Agmatine Antiglaucoma Eye Drops. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1244.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To develop a new antiglaucoma ophthalmic solution containing agmatine in the pre-commercialization stage.

Methods : A new antiglaucoma ophthalmic solution containing 1.0 mM agmatine sulfate has been developed in the pre-commercialization stage. Three candidate eye drops were formulated and their stability was checked for 6 months at both room temperature as well as in the refrigerator. Their ocular safety was carefully evaluated on the cornea of Sprague Dawley rats for 4 weeks. For the most promising agmatine candidate, its ocular hypotensive and neuroprotective effects were assessed for 3 weeks. In addition, its antiglaucoma effects were compared to a currently used antiglaucoma agent of brimonidine which is supposed to have most similar action mechanisms with agmatine among all commercialized antiglaucoma eye drops.

Results : Among 7 available sources of raw agmatine sulfate, the highest one with a purity of 99.92% as determined by high-performance liquid chromatography (HPLC) was selected. All three agmatine formulations were completely stable for at least 6 months and did not cause any apparent ophthalmic complications for 4 weeks. In the chronic ocular hypertensive Sprague Dawley rat models established by episcleral vein cauterization, the candidate agmatine eye drops decreased the intraocular pressures by 19.86% (from 36.50±2.38 mmHg to 29.25±2.06 mmHg) and preserved the intensity of retinal ganglion cell axon as assessed by immunofluorescence for alpha-tubulin.

Conclusions : A new antiglaucoma ophthalmic solution containing 1.0 mM agmatine sulfate has been successfully developed in the pre-commercialization stage. These promising eye drops have excellent ocular hypotensive and neuroprotective effects.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×